Navigation Links
The benefits of cardiac resynchronisation therapy in heart failure
Date:12/18/2011

However, large-scale clinical trials have highlighted the beneficial effect of cardiac resynchronisation therapy (CRT) in the improvement of symptoms and reduction of mortality, and CRT is now recommended in the major European and American guidelines for the treatment and prevention of heart failure.(1)

Clinical trials, however, are performed in carefully selected subjects and their results are not always applicable to the general population. Large-scale registries or surveys, on the other hand, capture data from a much more heterogeneous population and are closer to everyday clinical practice (although the applicability of the sample may be a concern).

Now, the European CRT Survey, whose follow-up results are published today in the European Journal of Heart Failure, suggests that CRT does indeed reduce rates of death and re-hospitalisation among heart failure patients.(2) Indeed, at one-year follow-up most patients who had received a CRT device considered their symptoms were better than their pre-implant assessment.(3)

The survey - a joint initiative of the Heart Failure Association and European Heart Rhythm Association of the European Society of Cardiology (ESC) - gathered information on more than 2000 patients at 141 centres in 13 European countries. Its aim was to assess the effect of CRT on symptom severity, cardiovascular re-hospitalisation, and survival. The study population included subjects poorly represented in clinical trials but commonly admitted as heart failure patients - including the very elderly, those with atrial fibrillation, and those previously treated with a pacemaker or other cardiac device.

Analysis of the survey data showed that at, one year (average) follow-up, 81% reported a self-assessed improvement in their symptoms (with 16% no change and 4% a deterioration).

The survey also found that almost 25% of the subjects had died or been re-hospitalised within the 12-month follow-up period. This poor outcome (who
'/>"/>

Contact: ESC Press Office
press@escardio.org
33-049-294-8627
European Society of Cardiology
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Publicly releasing inspection data on meat processing facilities could have substantial benefits
2. Does Psoriasis Thwart the Benefits of Good Cholesterol?
3. Kessler Foundation reports benefits of behavioral technique for cognitive rehabilitation in MS
4. Cooking Class Benefits Kids in Many Ways
5. Quality of life benefits of transcatheter aortic valve replacement differ by access site
6. Benefits of nut consumption for people with abdominal obesity, high blood sugar, high blood pressure
7. Increased use of bikes for commuting offers economic, health benefits
8. Glaucoma Experts Eye Benefits of Exercise
9. Religious, spiritual support benefits men and women facing chronic illness, MU study finds
10. USDA research demonstrates new breeds of broccoli remain packed with health benefits
11. BMC pediatricians find increase in SNAP benefits associated with healthier children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Today, Zane Benefits, the #1 ... a new eBook, Affordable Care Act 101. , ... feel uncertain about how the ACA impacts their ... line. , The new eBook outlines key ACA ... their upcoming health insurance decisions. , Read the ...
(Date:8/20/2014)... Locating rates for insurance packages will now be an ... new source of term life insurance providers has been added ... 50 states at http://quotespros.com/life-insurance.html . , The database ... available for the public to find out the exact annual ... quotations that are available are good through the rest of ...
(Date:8/20/2014)... group representing U.S. obstetricians is calling for all pregnant ... the American College of Obstetricians and Gynecologists (ACOG), several ... and effectiveness of flu vaccination during pregnancy. "The ... dangerous to pregnant women, as it can cause pneumonia, ... of the college,s Immunization Expert Work Group, explained in ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... a group of rhesus monkeys from deadly Marburg virus, a ... 90 percent of those it infects, researchers report. The ... virus, even when it was given three days after infection, ... Science Translational Medicine . This is the first ...
(Date:8/20/2014)... Line: Less than 42 percent of women underwent ... the factors associated with foregoing reconstruction included being ... older. , Author: Monica Morrow, M.D., of the ... colleagues. , Background: The Women,s Health and Cancer ... breast reconstruction following a mastectomy. Still, most women ...
Breaking Medicine News(10 mins):Health News:Term Life Insurance Price Database Now Helps Quote Prices for Adults in 50 States Online 2Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 3Health News:Patient perspectives on breast reconstruction following mastectomy 2
... By Tobacco Advertising and Find It,Easy to Buy Cigarettes, ... against tobacco on April 2 as they join thousands ... Day, sponsored by the Campaign,for Tobacco-Free Kids. Hundreds of ... local events, go to http://www.kickbuttsday.org/events )., This ...
... March 27 The Richard B. and,Lynne V. ... John Ray have joined the Institute,s Board of ... for the Institute., "Mary Matalin,s experience in ... to the Institute as we build our organization ...
... Calif., March 27 Clarient, Inc.,(Nasdaq: CLRT ), ... the pharmaceutical industry, today announced,that it is scheduled to ... Co.,9th Annual Las Vegas Investor Conference at 4:00 p.m. ... conference is being held at the Palms,Casino Resort April ...
... Now Have Choices and Flexibility ... Typically Available on Larger Plans, NEW YORK, ... to,nine employees can now choose from a wider selection of ... larger,companies., The Guardian Life Insurance Company of America (Guardian), ...
... a mental rigidity that keeps them from folding their ... form of mental rigidity that leads to compulsive behavior ... luck even when they,re on a losing streak, a ... causes compulsive gambling, but it,s been suggested that environmental ...
... CHICAGO, IL MARCH 27, 2008 The Cardiovascular ... meta-analysis to date comparing mortality rates for drug-eluting stents ... Stent Revolution VII meeting tomorrow evening in Chicago. ... studieswas performed by a team of researchers led by ...
Cached Medicine News:Health News:D.C. Kids 'Kick Butts' on April 2 2Health News:D.C. Kids 'Kick Butts' on April 2 3Health News:Mary Matalin and John Ray Join the Cheney Cardiovascular Institute Board of Directors 2Health News:Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference 2Health News:Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost 2Health News:Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost 3Health News:Compulsive Gamblers Don't Learn From Their Mistakes 2Health News:Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use 2
(Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Impact of ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... 3590) is complex legislation that affects virtually every ... provisions are beginning to take effect now. IVD ...
(Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and ... report to their offering. A ... and geography) - Size, Share, Global Trends, Company ... and Forecast, 2013 - 2020", suggests that the ...
Breaking Medicine Technology:Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2
... 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 2012.  For the first quarter of 2012, the Company reported ... compared with a net income of $2.9 million, or $0.05 ... $3.8 million change in operating results is primarily due to ...
... Janssen Research & Development, LLC, (Janssen), announced today ... to the U.S. Food and Drug Administration (FDA) seeking ... an oral anticoagulant, to treat patients with deep vein ... recurrent venous thromboembolism (VTE). These submissions are ...
Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8
Bone Curette, 170 mm...
Bone Currettes...
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
...
Medicine Products: